CareDx, Inc.
50.03USD
-0.2800 (-0.56%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.25▲ | $0.19 | 5 | 0 |
| Next quarter | $0.24▲ | $0.17 | 5 | 0 |
| Current year | $1.2▲ | $0.93 | 5 | 0 |
| Next year | $1.33▲ | $1.13 | 4 | 1 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.23 | $0.37 | +0.14 (+59.5%) |
| 2026-03-31 | $0.13 | $0.34 | +0.21 (+161.5%) |
| 2025-12-31 | $0.23 | $0.12 | -0.11 (-47.1%) |
| 2025-09-30 | $0.14 | $0.28 | +0.14 (+97.6%) |
93 ratings from 13 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Canaccord Genuity | Initiated | Buy | $65 | Sep 2, 2026 |
| BTIG | Maintained | Buy | $45 $60 | Aug 6, 2026 |
| HC Wainwright & Co. | Reiterated | Neutral | $46 | Jul 31, 2026 |
| BTIG | Maintained | Buy | $28 $45 | Jul 16, 2026 |
| BTIG | Maintained | Buy | $26 $28 | Apr 29, 2026 |
| BTIG | Maintained | Buy | $25 $26 | Feb 26, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $18 $21 | Feb 25, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $14 $18 | Dec 15, 2025 |
| BTIG | Maintained | Buy | $22 $25 | Nov 6, 2025 |
| BTIG | Reiterated | Buy | $22 | Sep 23, 2025 |
| BTIG | Reiterated | Buy | $22 | Sep 12, 2025 |
| William Blair | Initiated | Market Perform | — | Aug 26, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $19 $14 | Aug 8, 2025 |
| Craig-Hallum | Maintained | Buy | $40 $26 | Jul 18, 2025 |
| Stephens & Co. | Reiterated | Overweight | $40 | May 5, 2025 |
| HC Wainwright & Co. | Reiterated | Neutral | $25 | May 5, 2025 |
| Goldman Sachs | Maintained | Buy | $34 $26 | Apr 17, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $26 $25 | Mar 3, 2025 |
| Stephens & Co. | Reiterated | Overweight | $40 | Feb 27, 2025 |
| Wells Fargo | Upgraded from Underweight | Equal-Weight | $28 $24 | Jan 15, 2025 |
| HC Wainwright & Co. | Reiterated | Neutral | $26 | Jan 14, 2025 |
| BTIG | Maintained | Buy | $40 $35 | Nov 5, 2024 |
| HC Wainwright & Co. | Reiterated | Neutral | — | Oct 22, 2024 |
| Goldman Sachs | Maintained | Buy | $26 $35 | Oct 16, 2024 |
| Wells Fargo | Initiated | Underweight | $28 | Aug 27, 2024 |
85 filings from 16 insiders · 14 buy / 14 sell over 6m
Officers and directors of CDNA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| NOVACK JEFFREY ADAMGeneral Counsel | Sell | 2.7k | $46.15 | $124k | Aug 5, 2026 |
| BICKERSTAFF GEORGE W IIIDirector | Sell | 20.0k | $46.28 | $926k | Aug 5, 2026 |
| GOLDBERG MICHAEL DDirector | Sell | 44.7k | $47.06 | $2.10M | Aug 4, 2026 |
| COURNOYER CHRISTINE MDirector | Sell | 16.0k | $46.94 | $751k | Aug 4, 2026 |
| HANNA JOHN WALTER JRChief Executive Officer | Sell | 118.0k | $36.11 | $4.46M | Jul 16, 2026 |
| VALANTINE HANNAH A.Director | Sell | 28.8k | $36.14 | $1.04M | Jul 16, 2026 |
| HANNA JOHN WALTER JRChief Executive Officer | Exercise | 118.0k | $8.20 | $968k | Jul 16, 2026 |
| VALANTINE HANNAH A.Director | Exercise | 28.8k | $7.96 | $425k | Jul 16, 2026 |
| GOLDBERG MICHAEL DDirector | Grant | 1.7k | — | — | Jul 2, 2026 |
| HANNA JOHN WALTER JRChief Executive Officer | Sell | 40.0k | $29.00 | $1.17M | Jun 29, 2026 |
| HANNA JOHN WALTER JRChief Executive Officer | Exercise | 70.0k | $8.20 | $574k | Jun 29, 2026 |
| VALANTINE HANNAH A.Director | Sell | 12.1k | $23.11 | $280k | Jun 15, 2026 |
| HANNA JOHN WALTER JRChief Executive Officer | Sell | 17.7k | $24.03 | $425k | Jun 15, 2026 |
| COURNOYER CHRISTINE MDirector | Grant | 9.8k | — | — | Jun 12, 2026 |
| RIGGSBEE RICHARD BRYANDirector | Grant | 9.8k | — | — | Jun 12, 2026 |
| COHEN FREDERICK E. M.D. PH.D.Director | Grant | 9.8k | — | — | Jun 12, 2026 |
| VALANTINE HANNAH A.Director | Grant | 9.8k | — | — | Jun 12, 2026 |
| GUNASEKARAN SURESHDirector | Grant | 9.8k | — | — | Jun 12, 2026 |
| GOLDBERG MICHAEL DDirector | Grant | 9.8k | — | — | Jun 12, 2026 |
| BICKERSTAFF GEORGE W IIIDirector | Grant | 9.8k | — | — | Jun 12, 2026 |
No analyst notes on CDNA yet.
Analyst Ratings
7 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 5 | 3 | 0 | 0 | Buy2.38 |
| 1 mo ago | 0 | 4 | 3 | 0 | 0 | Buy2.43 |
| 2 mo ago | 0 | 3 | 4 | 0 | 0 | Hold2.57 |
| 3 mo ago | 0 | 3 | 4 | 0 | 0 | Hold2.57 |